Chugai Pharmaceutical Co.

Chugai Seiyaku Kabushiki Kaisha

Mitsui Chemicals, Inc.

Yoshihiro Matsumoto

Masayuki Tsuchiya

Kouji Matsushima

Koh Sato

Yoshiki Yamada

Tatsumi Yamazaki

Satoshi Yamasaki

Toshihiko Nakagawa

Takashi Uchida

Shinji Tachibana

Takashi Kanno

Tatsuya Shibata

Hideaki Ootsuka

A polyisocyanate composition is produced by reaction of bis(isocyanatomethyl) cyclohexane with trimethylolpropane, and contains a trimethylolpropane-monomolecular-body obtained by reaction of three molecules of bis(isocyanatomethyl) cyclohexane with one molecule of trimethylolpropane, and a trimethylolpropane-bimolecular-body obtained by reaction of five molecules of bis(isocyanatomethyl) cyclohexane with two molecules of trimethylolpropane; and the molar ratio of trimethylolpropane-monomolecular-body relative to trimethylolpropane-bimolecular-body (trimethylolpropane-monomolecular-body/trimethylolpropane-bimolecular-body) contained in the polyisocyanate composition is 1.5 or more and 4.5 or less.

Polyisocyanate composition, solar cell member covering material, solar cell member with cover layer, microcapsule, and binder for ink

A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. The reshaped antibody has the following elements: a human L chain C region or a human L chain FR and an L chain CDR from a mouse monoclonal antibody against human IL-8 and a human H chain C region or a human H chain FR and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the reshaped human antibody has low immunogenicity to humans, it is suitable for use in medical treatment of a variety of medical conditions.

Reshaped human antibody to human interleukin-8

Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.

Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing

Recombinant materials for producing humanized anti-IL-8 antibodies

Method to treat inflammation with humanized anti-IL-8-antibodies

Polynucleotides which encode reshaped IL-8-specific antibodies and

Growing community of inventors

Shizuoka, Japan

Yoshihiro Matsumoto